🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against superbug strains of the infection, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting more than 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Data and Global Access

According to data published in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The trial involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. The availability of a one-pill regimen of this kind is seen as a "critical tool" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea worldwide.